News

The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary

The Depletion of serum amyloid P component in Alzheimer’s disease (DESPIAD) trial will test whether a drug called miridesap removes a protein associated with the disease from the

Designed to Current Good Manufacturing Practices (cGMP) specifications and certified by the Belgian Federal Agency for Medicines and Healthcare Products, the new €5m facility, adjacent to its headquarters

The confirmation came from the new sub-analysis data from the Euro-Esli study of eslicarbazepine acetate for focal-onset seizures in more than 2,000 patients. Bial and Eisai said that

The breakthrough preclinical study demonstrated that highly optimized dMAbs targeting mouse CTLA-4 protein can be robustly expressed in vivo, and shrank tumors in mice. More importantly, Inovio’s dMAb

Chronocort was not successful in confirming its superiority over conventional treatment in endocrine control over a 24-hour period during the late-stage clinical trial held in Europe. Diurnal Group

The regulators have accepted the firm’s filings for investigational oral and once-daily siponimod to treat secondary progressive multiple sclerosis (SPMS) in adults. Siponimod is an investigational and selective

The two studies are projected to deliver a total of c.£9m in revenue, with most of the revenue being recognised in 2019. These contracts are in addition to

The company, founded with seed funding from SV Health investors, raised a total of $30 million from a syndicate of specialist international healthcare investors co-led by SV Health